Literature DB >> 21827920

Episodic ataxias 1 and 2.

Robert W Baloh1.   

Abstract

The episodic ataxias are autosomal dominant disorders usually beginning in the first two decades of life. Episodic ataxia type 1 (EA1) is characterized by brief episodes of ataxia, typically lasting seconds, and interictal myokymia, while episodic ataxia type 2 (EA2) is manifested by longer episodes of ataxia (hours) with interictal nystagmus. The EA1 gene (KCNA1) codes for the six transmembrane segments (S1 to S6) of the Kv1.1 potassium channel subunit and the EA2 gene (CACNA1A) encodes for the Ca(v)2.1 subunit of the P/Q calcium channel complex. EA1 mutations are always missense while most EA2 mutations disrupt the reading frame. Studies of the biophysical properties of the mutant Kv1.1 and Ca(v)2.1 channels in Xenopus oocytes and mammalian cell lines demonstrate clear physiologic consequences of the genetic mutations although no consistent pattern for genotype-phenotype correlation has emerged. Genetic testing for EA1 and EA2 is available, but since no single mutation is prominent for either KCNA1 or CACNA1A, all of the coding regions of the genes need to be screened for mutations. Acetazolamide can be dramatic in controlling episodes of ataxia with EA2 but is typically less beneficial with EA1. 2012 Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 21827920     DOI: 10.1016/B978-0-444-51892-7.00042-5

Source DB:  PubMed          Journal:  Handb Clin Neurol        ISSN: 0072-9752


  13 in total

1.  Clinical heterogeneity associated with KCNA1 mutations include cataplexy and nonataxic presentations.

Authors:  Catherine A Brownstein; Alan H Beggs; Lance Rodan; Jiahai Shi; Meghan C Towne; Renee Pelletier; Siqi Cao; Paul A Rosenberg; David K Urion; Jonathan Picker; Wen-Hann Tan; Pankaj B Agrawal
Journal:  Neurogenetics       Date:  2015-09-22       Impact factor: 2.660

Review 2.  The Clinical Spectrum of Autosomal-Dominant Episodic Ataxias.

Authors:  Stefan Kipfer; Michael Strupp
Journal:  Mov Disord Clin Pract       Date:  2014-07-28

3.  Abnormal excitability and episodic low-frequency oscillations in the cerebral cortex of the tottering mouse.

Authors:  Samuel W Cramer; Laurentiu S Popa; Russell E Carter; Gang Chen; Timothy J Ebner
Journal:  J Neurosci       Date:  2015-04-08       Impact factor: 6.167

4.  Ubiquitin Ligase RNF138 Promotes Episodic Ataxia Type 2-Associated Aberrant Degradation of Human Cav2.1 (P/Q-Type) Calcium Channels.

Authors:  Ssu-Ju Fu; Chung-Jiuan Jeng; Chia-Hao Ma; Yi-Jheng Peng; Chi-Ming Lee; Ya-Ching Fang; Yi-Ching Lee; Sung-Chun Tang; Meng-Chun Hu; Chih-Yung Tang
Journal:  J Neurosci       Date:  2017-02-06       Impact factor: 6.167

5.  A novel de novo pathogenic mutation in the CACNA1A gene.

Authors:  Shinsuke Fujioka; Sruti Rayaprolu; Christina Sundal; Daniel F Broderick; William A Langley; John Shoffner; Lauren C Hyams; Rosa Rademakers; Neill R Graff-Radford; William Tatum; Owen A Ross; Zbigniew K Wszolek
Journal:  Mov Disord       Date:  2012-10-04       Impact factor: 10.338

Review 6.  Application of Mouse Models to Research in Hearing and Balance.

Authors:  Kevin K Ohlemiller; Sherri M Jones; Kenneth R Johnson
Journal:  J Assoc Res Otolaryngol       Date:  2016-10-17

Review 7.  Genetics of peripheral vestibular dysfunction: lessons from mutant mouse strains.

Authors:  Sherri M Jones; Timothy A Jones
Journal:  J Am Acad Audiol       Date:  2014-03       Impact factor: 1.664

8.  The first knockin mouse model of episodic ataxia type 2.

Authors:  Samuel J Rose; Lisa H Kriener; Ann K Heinzer; Xueliang Fan; Robert S Raike; Arn M J M van den Maagdenberg; Ellen J Hess
Journal:  Exp Neurol       Date:  2014-08-08       Impact factor: 5.330

9.  Translating cerebellar Purkinje neuron physiology to progress in dominantly inherited ataxia.

Authors:  Ravi Chopra; Vikram G Shakkottai
Journal:  Future Neurol       Date:  2014-03-01

10.  Consensus paper: pathological mechanisms underlying neurodegeneration in spinocerebellar ataxias.

Authors:  A Matilla-Dueñas; T Ashizawa; A Brice; S Magri; K N McFarland; M Pandolfo; S M Pulst; O Riess; D C Rubinsztein; J Schmidt; T Schmidt; D R Scoles; G Stevanin; F Taroni; B R Underwood; I Sánchez
Journal:  Cerebellum       Date:  2014-04       Impact factor: 3.847

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.